Atherosclerosis
Volume 212, Issue 2 , Pages 388-389 , October 2010

Novel insights into anti-inflammatory actions of HDL

  • Diederik F. van Wijk

      Affiliations

    • Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    • ,
  • Erik S.G. Stroes

      Affiliations

    • Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    • ,
  • G.M. Dallinga-Thie

      Affiliations

    • Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    • Department of Experimental Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author at: Academic Medical Center, Department of Experimental Vascular Medicine, G1-113, PO Box 22660, 1100 DD Amsterdam, The Netherlands. Tel.: +31 20 566 5158; fax: +31 20 566 9343.

Received 8 June 2010 ,Accepted 15 June 2010.

References 

  1. Vergeer M, Holleboom AG, Kastelein JJ, Kuivenhoven JA. The HDL hypothesis—does high-density lipoprotein protect from atherosclerosis?. J Lipid Res. 2010;
  2. Tall AR. An overview of reverse cholesterol transport. Eur Heart J. 1998;19(Suppl. A):A31–A35
  3. Feig JE, Shamir R, Fisher EA. Atheroprotective effects of HDL: beyond reverse cholesterol transport. Curr Drug Targets. 2008;9:196–203
  4. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 1995;15:1987–1994
  5. Park SH, Park JH, Kang JS, Kang YH. Involvement of transcription factors in plasma HDL protection against TNF-alpha-induced vascular cell adhesion molecule-1 expression. Int J Biochem Cell Biol. 2003;35:168–182
  6. Davies MJ, Gordon JL, Gearing AJ, et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol. 1993;171:223–229
  7. Murphy AJ, Woollard KJ, Hoang A, et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol. 2008;28:2071–2077
  8. Aviram M, Brook JG. Plastelet interaction with high and low density lipoproteins. Atherosclerosis. 1983;46:259–268
  9. Aviram M, Brook JG. Characterization of the effect of plasma lipoproteins on platelet function in vitro. Haemostasis. 1983;13:344–350
  10. Hassall DG, Owen JS, Bruckdorfer KR. The aggregation of isolated human platelets in the presence of lipoproteins and prostacyclin. Biochem J. 1983;216:43–49
  11. Nicholls SJ, Dusting GJ, Cutri B, et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation. 2005;111:1543–1550
  12. Puranik R, Bao S, Nobecourt E, et al. Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo. Atherosclerosis. 2008;196:240–247
  13. McGrath KC, Li XH, Puranik R, et al. Role of 3beta-hydroxysteroid-delta 24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol. 2009;29:877–882
  14. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein 1. N Engl J Med. 2008;359:2195–2207
  15. Tardif JC, Gregoire J, L’Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007;297:1675–1682

PII: S0021-9150(10)00450-8

doi: 10.1016/j.atherosclerosis.2010.06.032

Atherosclerosis
Volume 212, Issue 2 , Pages 388-389 , October 2010

Article Tools